France· FR:61673965
VIMIZIM 1 mg/ml, solution à diluer pour perfusion
A elosulfase alfa product containing élosulfase alfa, registered in France by BIOMARIN INTERNATIONAL LIMITED (IRLANDE). The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Elosulfase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB12 (elosulfase alfa), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Elosulfase alfa · ATC A16AB12
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ÉLOSULFASE ALFA
- Manufacturer
- BIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- Country
- France (FR)
- ATC code
- A16AB12
- ATC class
- Elosulfase alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009586727051 flacon(s) en verre
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elosulfase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsVimizim 1 mg/ml concentraat voor oplossing voor infusieBioMarin International Limited
- Japanエロスルファーゼ アルファ（遺伝子組換え）ＢｉｏＭａｒｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｊａｐａｎ
- United KingdomVimizim 5mg/5ml concentrate for solution for infusion vialsBioMarin (U.K.) Ltd
- NorwayVimizimBioMarin International Limited
- CzechiaVIMIZIMBioMarin International Limited, Dublin
- SpainVIMIZIM 1MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBiomarin International Limited
- FinlandVimizimBiomarin International Limited
- IrelandVimizim 1 mg/ml concentrate for solution for infusionBiomarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vimizim
- Liechtenstein · Vimizim
- Norway · Vimizim
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/848e665e-f3fa-499a-a7f5-5e52507fe5ab GET /v1/drugs/848e665e-f3fa-499a-a7f5-5e52507fe5ab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61673965",
"date_amm": "2014-04-28",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/914",
"substance": "ÉLOSULFASE ALFA",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about elosulfase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.